AAAAAA
Results:
1-14
|
Results: 14
Authors:
Bellmunt, J
de Wit, R
Albanell, J
Baselga, J
Citation: J. Bellmunt et al., A feasibility study of carboplatin with fixed dose of gemcitabine in 'unfit' patients with advanced bladder cancer, EUR J CANC, 37(17), 2001, pp. 2212-2215
Authors:
Baselga, J
Albanell, J
Citation: J. Baselga et J. Albanell, Mechanism of action of anti-HER2 monoclonal antibodies, ANN ONCOL, 12, 2001, pp. 35-41
Authors:
Baselga, J
Albanell, J
Molina, MA
Arribas, J
Citation: J. Baselga et al., Mechanism of action of trastuzumab and scientific update, SEMIN ONCOL, 28(5), 2001, pp. 4-11
Authors:
Albanell, J
Rojo, F
Baselga, J
Citation: J. Albanell et al., Pharmacodynamic studies with the epidermal growth factor receptor tyrosinekinase inhibitor ZD1839, SEMIN ONCOL, 28(5), 2001, pp. 56-66
Authors:
Albanell, J
Codony-Servat, J
Rojo, F
Del Campo, JM
Sauleda, S
Anido, J
Raspall, G
Giralt, J
Rosello, J
Nicholson, RI
Mendelsohn, J
Baselga, J
Citation: J. Albanell et al., Activated extracellular signal-regulated kinases: Association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments, CANCER RES, 61(17), 2001, pp. 6500-6510
Authors:
Molina, MA
Codony-Servat, J
Albanell, J
Rojo, F
Arribas, J
Baselga, J
Citation: Ma. Molina et al., Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells, CANCER RES, 61(12), 2001, pp. 4744-4749
Authors:
Bellmunt, J
Guillem, V
Paz-Ares, L
Gonzalez-Larriba, JL
Carles, J
Albanell, J
Tabernero, JM
Cortes-Funes, H
Baselga, J
Citation: J. Bellmunt et al., Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer, EUR J CANC, 36, 2000, pp. S17-S25
Authors:
Bellmunt, J
Guillem, V
Paz-Ares, L
Gonzalez-Larriba, JL
Carles, J
Batiste-Alentorn, E
Saenz, A
Lopez-Brea, M
Font, A
Nogue, M
Bastus, R
Climent, MA
de la Cruz, JJ
Albanell, J
Banus, JM
Gallardo, E
Diaz-Rubio, E
Cortes-Funes, H
Baselga, J
Citation: J. Bellmunt et al., Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium, J CL ONCOL, 18(18), 2000, pp. 3247-3255
Authors:
Albanell, J
Baselga, J
Citation: J. Albanell et J. Baselga, Systemic therapy emergencies, SEMIN ONCOL, 27(3), 2000, pp. 347-361
Authors:
Albanell, J
Bosl, GJ
Reuter, VE
Engelhardt, M
Franco, S
Moore, MAS
Dmitrovsky, E
Citation: J. Albanell et al., Telomerase activity in germ cell cancers and mature teratomas, J NAT CANC, 91(15), 1999, pp. 1321-1326
Authors:
Albanell, J
Baselga, J
Citation: J. Albanell et J. Baselga, The ErbB receptors as targets for breast cancer therapy, J MAMMARY G, 4(4), 1999, pp. 337-351
Authors:
Albanell, J
Baselga, J
Citation: J. Albanell et J. Baselga, Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer, DRUGS TODAY, 35(12), 1999, pp. 931-946
Authors:
Baselga, J
Norton, L
Albanell, J
Kim, YM
Mendelsohn, J
Citation: J. Baselga et al., Recombinant humanized anti-HER2 antibody (Herceptin (TM)) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts (vol 58, pg 2825, 1998), CANCER RES, 59(8), 1999, pp. 2020-2020
Authors:
Codony-Servat, J
Albanell, J
Lopez-Talavera, JC
Arribas, J
Baselga, J
Citation: J. Codony-servat et al., Cleavage of the HER2 ectodomain is a pervanadate-activable process that isinhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells, CANCER RES, 59(6), 1999, pp. 1196-1201
Risultati:
1-14
|